These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29105742)

  • 41. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Classifying ultra-high risk smoldering myeloma.
    Waxman AJ; Mick R; Garfall AL; Cohen A; Vogl DT; Stadtmauer EA; Weiss BM
    Leukemia; 2015 Mar; 29(3):751-3. PubMed ID: 25371175
    [No Abstract]   [Full Text] [Related]  

  • 43. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
    Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma.
    Coffey DG; Wu QV; Towlerton AMH; Ornelas S; Morales AJ; Xu Y; Green DJ; Warren EH
    Blood Cancer J; 2019 Sep; 9(10):77. PubMed ID: 31570697
    [No Abstract]   [Full Text] [Related]  

  • 45. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
    Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients.
    Shires K; Wienand K
    J Cancer Res Clin Oncol; 2016 Nov; 142(11):2383-96. PubMed ID: 27581737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.
    Frébet E; Abraham J; Geneviève F; Lepelley P; Daliphard S; Bardet V; Amsellem S; Guy J; Mullier F; Durrieu F; Venon MD; Leleu X; Jaccard A; Faucher JL; Béné MC; Feuillard J;
    Cytometry B Clin Cytom; 2011 May; 80(3):176-85. PubMed ID: 21520405
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation.
    Gertz MA; Witzig TE; Pineda AA; Greipp PR; Kyle RA; Litzow MR
    Bone Marrow Transplant; 1997 Feb; 19(4):337-42. PubMed ID: 9051243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
    Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
    Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
    [TBL] [Abstract][Full Text] [Related]  

  • 50. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.
    Gonsalves WI; Rajkumar SV; Gupta V; Morice WG; Timm MM; Singh PP; Dispenzieri A; Buadi FK; Lacy MQ; Kapoor P; Gertz MA; Kumar SK
    Leukemia; 2014 Oct; 28(10):2060-5. PubMed ID: 24618735
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
    Pérez-Persona E; Mateo G; García-Sanz R; Mateos MV; de Las Heras N; de Coca AG; Hernández JM; Galende J; Martín-Nuñez G; Bárez A; Alonso JM; Martín A; López-Berges C; Orfao A; San Miguel JF; Vidriales MB
    Br J Haematol; 2010 Jan; 148(1):110-4. PubMed ID: 19821821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma.
    Yuan CM; Stetler-Stevenson M
    Semin Hematol; 2011 Jan; 48(1):32-8. PubMed ID: 21232656
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
    Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
    Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utility of nine-color, 11-parameter flow cytometry for detection of plasma cell neoplasms: a comparison with bone marrow morphologic findings and concurrent M-protein studies in serum and urine.
    Behdad A; Ross CW; Jacques J; Kota U; Keren D; Stoolman L
    Am J Clin Pathol; 2014 Sep; 142(3):398-410. PubMed ID: 25125632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
    Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
    Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders.
    Basile U; Gulli F; Isgrò MA; Napodano C; Pocino K; Santini SA; Gragnani L; Conti L; Rossi E; Cordone I; Zignego AL; Rapaccini GL; Cigliana G; Berruti F; Todi L; Marino M; Di Stasio E
    Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4293-4302. PubMed ID: 31173301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias.
    Ozsan GH; Dispenzieri A
    Expert Rev Clin Immunol; 2011 Jan; 7(1):65-73. PubMed ID: 21162651
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of circulating plasma cells in peripheral blood using deep learning-based morphological analysis.
    Chen P; Zhang L; Cao X; Jin X; Chen N; Zhang L; Zhu J; Pan B; Wang B; Guo W
    Cancer; 2024 May; 130(10):1884-1893. PubMed ID: 38236717
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma cell morphology in multiple myeloma and related disorders.
    Ribourtout B; Zandecki M
    Morphologie; 2015 Jun; 99(325):38-62. PubMed ID: 25899140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.